Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Hangzhou Diagens Biotechnology Co., Ltd.
杭州德適生物科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2526)

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

This announcement is made pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

The board (the "**Board**") of directors (the "**Directors**") of Hangzhou Diagens Biotechnology Co., Ltd. (the "**Company**") hereby announces that on April 29, 2026, the Board resolved to propose amendments to the articles of association of the Company (the "**Articles of Association**").

The China Securities Regulatory Commission amended the Guidelines for the Articles of Association of Listed Companies in March 2025. Meanwhile, the Company conducted its initial public offering and was listed on the Main Board of the Stock Exchange on March 30, 2026, having issued 7,999,200 overseas listed foreign ordinary shares with a nominal value of RMB1.00 per share ("**H Shares**"), and converted all of its original unlisted shares into H Shares. Upon completion of this public offering, the share capital of the Company comprises 88,879,200 shares, all of which are H Shares.

In view of the above, the Board proposes to amend the Articles of Association to, among other things, (i) reflect updates in regulatory requirements and changes in the share capital structure of the Company, so as to bring the Articles of Association in line with the latest applicable laws and regulations and further improve the corporate governance structure of the Company, and (ii) incorporate certain housekeeping amendments (the "**Proposed Amendments**").

The Proposed Amendments are subject to the approval of the shareholders of the Company by way of a special resolution at the forthcoming annual general meeting of the Company (the "**AGM**") before they become effective. A circular containing, among other things, further details of the Proposed Amendments will be despatched to the shareholders of the Company in due course.

By order of the Board
Hangzhou Diagens Biotechnology Co., Ltd.
Song Ning
Chairman and Executive Director

Hangzhou, the PRC, April 29, 2026

As of the date of this announcement, the board of directors of the Company comprises (i) Dr. Song Ning and Mr. Weng Chih-Hsin (alias Robin Weng) as executive directors; (ii) Dr. Xu Chen, Dr. Wu Lingqian and Mr. Yang Zehao as non-executive directors; and (iii) Mr. Cha Yang (alias Stanley Cha), Ms. Zhang Jing and Mr. Wang Kaifeng as independent non-executive directors.